AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25874510 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 days of octreotide infusion (50 μg/kg)
Number of subjects: 124
Study 25874510 — intervention group
Group type: COMPARATOR
Intervention: 5 days of octreotide infusion (50 μg/kg)
Number of subjects: 124
Study 23837630 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal red blood cell (RBC) transfusion policy
Number of subjects: 0
Study 23837630 — intervention group
Group type: COMPARATOR
Intervention: Restrictive red blood cell (RBC) transfusion policy
Number of subjects: 0
Study 21823284 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus acupoint injection with Methylcobalamin (group A)
Number of subjects: 60
Study 21823284 — intervention group
Group type: COMPARATOR
Intervention: Acupoint injection with Methylcobalamin (group B)
Number of subjects: 60
Study 19861283 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrase therapy (intravenous infusion at doses of 15, 10, and 5 U based on plasma FIB levels)
Number of subjects: 60
Study 19861283 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrase therapy
Number of subjects: 60
Study 19861283 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study 17559450 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional method with local anaesthesia
Number of subjects: 299
Study 17559450 — intervention group
Group type: COMPARATOR
Intervention: Conventional method without local anaesthesia
Number of subjects: 299
Study 17559450 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART) with local anaesthesia
Number of subjects: 299
Study 17559450 — intervention group
Group type: COMPARATOR
Intervention: Atraumatic restorative treatment (ART) without local anaesthesia
Number of subjects: 299
Study 15768820 — intervention group
Group type: EXPERIMENTAL
Intervention: hylan B gel (n =47)
Number of subjects: 70
Study 15768820 — intervention group
Group type: COMPARATOR
Intervention: collagen (n =23)
Number of subjects: 70
Study 11454146 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 administered at the onset of a standard meal (550 kCal)
Number of subjects: 8
Study 11454146 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 administered at 30 min after the start of the meal
Number of subjects: 8
Study 11454146 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 administered at 60 min after the start of the meal
Number of subjects: 8
Study 11454146 — intervention group
Group type: COMPARATOR
Intervention: Control meal
Number of subjects: 8
Study 9491969 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaprozin (1200 mg)
Number of subjects: 12
Study 9491969 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine oxaprozin standards
Number of subjects: 12
Study 7487368 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 79
Study 7487368 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroid antiinflammatory drugs (NSAID)
Number of subjects: 79
Study 2725277 — intervention group
Group type: EXPERIMENTAL
Intervention: Trilostane 240 mg/d (Trilo 240)
Number of subjects: 22
Study 2725277 — intervention group
Group type: EXPERIMENTAL
Intervention: Trilostane 60 mg/d (Trilo 60)
Number of subjects: 22
Study 2725277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 29939279 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg subcutaneously twice daily for 4 weeks)
Number of subjects: 67
Study 29939279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 28954789 — intervention group
Group type: EXPERIMENTAL
Intervention: HeLP-Diabetes (web-based self-management programme)
Number of subjects: 374
Study 28954789 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 374
Study 26078237 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition with monitoring of gastric residual volume (GRV)
Number of subjects: 210
Study 26078237 — intervention group
Group type: COMPARATOR
Intervention: Enteral nutrition without monitoring of gastric residual volume (GRV)
Number of subjects: 210
Study 23250341 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylergonovine
Number of subjects: 80
Study 23250341 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 80
Study 21326271 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra virgin olive oil
Number of subjects: 67
Study 21326271 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy oil
Number of subjects: 67
Study 21326271 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod liver oil
Number of subjects: 67
Study 21326271 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn oil
Number of subjects: 67
Study 21326271 — intervention group
Group type: EXPERIMENTAL
Intervention: All types of oil
Number of subjects: 67
Study 19259349 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative prophylactic antibiotics (1.0 g Cefpiramide twice daily until the third day after surgery)
Number of subjects: 56
Study 19259349 — intervention group
Group type: COMPARATOR
Intervention: Control group (no postoperative prophylactic antibiotics)
Number of subjects: 56
Study 17239889 — intervention group
Group type: EXPERIMENTAL
Intervention: Low levels of adiponectin (lowest quartile)
Number of subjects: 142
Study 17239889 — intervention group
Group type: COMPARATOR
Intervention: Adiponectin levels (second to fourth quartile)
Number of subjects: 142
Study 17239889 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measures of IMT and distensibility
Number of subjects: 142
Study 17239889 — intervention group
Group type: EXPERIMENTAL
Intervention: After 12 months
Number of subjects: 142
Study 17239889 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for confounding factors
Number of subjects: 142
Study 17239889 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin levels
Number of subjects: 142
Study 15088038 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser irradiation (wavelength 10.6 mm)
Number of subjects: 40
Study 15088038 — intervention group
Group type: COMPARATOR
Intervention: Control samples (not subjected to laser irradiation)
Number of subjects: 40
Study 15088038 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA (root end filling material)
Number of subjects: 40
Study 15088038 — intervention group
Group type: EXPERIMENTAL
Intervention: Gutta percha (root end filling material)
Number of subjects: 40
Study 11682393 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 0
Study 11682393 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 0
Study 8860099 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 12.5 mg (LD-CAP)
Number of subjects: 35
Study 8860099 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg (HD-CAP)
Number of subjects: 35
Study 8860099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 2179367 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release albuterol
Number of subjects: 124
Study 2179367 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release theophylline
Number of subjects: 124
Study 94402 — intervention group
Group type: COMPARATOR
Intervention: Probucol, 500 mg twice daily for 20 weeks
Number of subjects: 9
Study 30840640 — intervention group
Group type: EXPERIMENTAL
Intervention: High physical exertion and high cognitive engagement (combo group)
Number of subjects: 142
Study 30840640 — intervention group
Group type: EXPERIMENTAL
Intervention: Low physical exertion and high cognitive engagement (cognition group)
Number of subjects: 142
Study 30840640 — intervention group
Group type: COMPARATOR
Intervention: High physical exertion and low cognitive engagement (aerobic group)
Number of subjects: 142
Study 28514081 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss Plus
Number of subjects: 409
Study 28514081 — intervention group
Group type: COMPARATOR
Intervention: Weight Loss Only
Number of subjects: 409
Study 25876706 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral OKT3 5.0 mg/day (Group D)
Number of subjects: 36
Study 25876706 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral OKT3 1.0 mg/day (Group C)
Number of subjects: 36
Study 25876706 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral OKT3 0.2 mg/day (Group B)
Number of subjects: 36
Study 25876706 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group A)
Number of subjects: 36
Study 25016366 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior activation (BA) + low vision rehabilitation (LVR)
Number of subjects: 188
Study 25016366 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy (ST) + low vision rehabilitation (LVR)
Number of subjects: 188
Study 22503761 — intervention group
Group type: EXPERIMENTAL
Intervention: Exisulind (375‐400 mg) daily for 4 weeks
Number of subjects: 93
Study 22503761 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine RP)
Number of subjects: 93
Study 20607509 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring tendon grafts (ST and GT)
Number of subjects: 0
Study 20607509 — intervention group
Group type: COMPARATOR
Intervention: Bone-patellar-tendon graft (BPT)
Number of subjects: 0
Study 20607509 — intervention group
Group type: EXPERIMENTAL
Intervention: Both grafts (Hamstring and BPT)
Number of subjects: 0
Study 17591514 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program designed to improve care for somatizing patients
Number of subjects: 911
Study 17591514 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 911
Study 16261546 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty
Number of subjects: 450
Study 16261546 — intervention group
Group type: COMPARATOR
Intervention: Stent implantation
Number of subjects: 450
Study 12117397 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (conjugated equine estrogens 0.625 mg/d plus medroxyprogesterone acetate 2.5 mg/d)
Number of subjects: 16608
Study 10421920 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine pre-operative injection (3 ml, 7.5 mg/ml)
Number of subjects: 80
Study 10421920 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine post-operative injection (3 ml, 7.5 mg/ml)
Number of subjects: 80
Study 10421920 — intervention group
Group type: COMPARATOR
Intervention: NaCl pre-operative injection (3 ml)
Number of subjects: 80
Study 10421920 — intervention group
Group type: COMPARATOR
Intervention: NaCl post-operative injection (3 ml)
Number of subjects: 80
Study 8862216 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Event Monitoring System (MEMS)
Number of subjects: 94
Study 8862216 — intervention group
Group type: EXPERIMENTAL
Intervention: Pill count
Number of subjects: 94
Study 8862216 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MEMS and pill count adherence
Number of subjects: 94
Study 8862216 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadherence by one or both methods
Number of subjects: 94
Study 1346408 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular artemether (4 mg/kg loading dose followed by 2 mg/kg daily)
Number of subjects: 73
Study 1346408 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular chloroquine (3.5 mg base/kg every 6 h)
Number of subjects: 73
Study 1346408 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular artemether
Number of subjects: 73
Study 1346408 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular chloroquine
Number of subjects: 73
Study 1346408 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular artemether and chloroquine
Number of subjects: 73
Study 6429092 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily fractionation of radiation (12-13 MeV electron beams)
Number of subjects: 0
Study 6429092 — intervention group
Group type: COMPARATOR
Intervention: Twice-a-week fractionation of radiation (12-13 MeV electron beams)
Number of subjects: 0
Study 6429092 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative radiation effect (CRE) formula
Number of subjects: 0
Study 6429092 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso-effect relationship
Number of subjects: 0
Study 6429092 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose range of 30 fractions between 1.6 and 2.1 Gy in 6 weeks
Number of subjects: 0
Study 30804310 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic lozenge (twice daily for 1 month)
Number of subjects: 60
Study 30804310 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenge (twice daily for 1 month)
Number of subjects: 60
Study 29907956 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined fractional CO2 laser and long pulsed Nd : YAG (1064 nm) laser
Number of subjects: 20
Study 29907956 — intervention group
Group type: COMPARATOR
Intervention: Long pulsed Nd : YAG (1064 nm) laser
Number of subjects: 20
Study 27286045 — intervention group
Group type: EXPERIMENTAL
Intervention: MIPPO
Number of subjects: 84
Study 27286045 — intervention group
Group type: EXPERIMENTAL
Intervention: IMN
Number of subjects: 84
Study 27286045 — intervention group
Group type: EXPERIMENTAL
Intervention: EF + LORIF
Number of subjects: 84
Study 27286045 — intervention group
Group type: COMPARATOR
Intervention: EF + LORIF, MIPPO, IMN
Number of subjects: 84
Study 25407583 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-administered cognitive behavioral therapy (T‐CBT)
Number of subjects: 325
Study 25407583 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face administered cognitive behavioral therapy (FtF‐CBT)
Number of subjects: 325
Study 22464708 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular simulator training (group A and group B)
Number of subjects: 80
Study 22464708 — intervention group
Group type: COMPARATOR
Intervention: No further training (group A after initial exposure)
Number of subjects: 80
Study 22464708 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular simulator training (group B after initial exposure)
Number of subjects: 80
Study 20816836 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 μg/wk peginterferon alfa‐2a for 48 weeks plus 1200 mg/day ribavirin (group A)
Number of subjects: 1145
Study 20816836 — intervention group
Group type: EXPERIMENTAL
Intervention: 1400/1600 mg/day ribavirin (group B)
Number of subjects: 1145
Study 20816836 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 μg/wk peginterferon alfa‐2a for 12 weeks then 180 μg/wk peginterferon alfa‐2a for 36 weeks plus 1200 mg/day ribavirin (group C)
Number of subjects: 1145
Study 20816836 — intervention group
Group type: EXPERIMENTAL
Intervention: 1400/1600 mg/day ribavirin (group D)
Number of subjects: 1145
Study 20816836 — intervention group
Group type: COMPARATOR
Intervention: Pooled peginterferon alfa‐2a regimens (A + B)
Number of subjects: 1145
Study 20816836 — intervention group
Group type: COMPARATOR
Intervention: Pooled ribavirin regimens (A + C)
Number of subjects: 1145
Study 17993096 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol in a mixture of 50% N2O and 50% oxygen (group P2)
Number of subjects: 160
Study 17993096 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental in a mixture of 50% N2O and 50% oxygen (group T2)
Number of subjects: 160
Study 17993096 — intervention group
Group type: COMPARATOR
Intervention: Propofol in 100% oxygen (group P1)
Number of subjects: 160
Study 17993096 — intervention group
Group type: COMPARATOR
Intervention: Thiopental in 100% oxygen (group T1)
Number of subjects: 160
Study 15452896 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-loss levels of posttraumatic stress symptoms (intrusion and avoidance)
Number of subjects: 50
Study 15452896 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-loss levels of posttraumatic stress symptoms
Number of subjects: 50
Study 15452896 — intervention group
Group type: EXPERIMENTAL
Intervention: Current level of perceived stress
Number of subjects: 50
Study 15452896 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipated impact of the loss
Number of subjects: 50
Study 11887035 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 155
Study 11887035 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving treatment from research nurse
Number of subjects: 155
Study 11887035 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication and combination treatment
Number of subjects: 155
Study 11887035 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 155
Study 11887035 — intervention group
Group type: EXPERIMENTAL
Intervention: All four treatments
Number of subjects: 155
Study 9812111 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 2-3 mg/day (standard dose)
Number of subjects: 71
Study 9812111 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 0.50-0.75 mg/day (low dose)
Number of subjects: 71
Study 9812111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 9812111 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 2-3 mg/day (standard dose) in phase B
Number of subjects: 71
Study 9812111 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose haloperidol in phase B
Number of subjects: 71
Study 9812111 — intervention group
Group type: COMPARATOR
Intervention: Placebo in phase B
Number of subjects: 71
Study 7631024 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Gy in ten fractions, five fractions a week (5F/W)
Number of subjects: 217
Study 7631024 — intervention group
Group type: COMPARATOR
Intervention: 15 Gy in three fractions, two fractions a week (2F/W)
Number of subjects: 217
Study 7631024 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimes (30 Gy in ten fractions and 15 Gy in three fractions)
Number of subjects: 217
Study 2204696 — intervention group
Group type: EXPERIMENTAL
Intervention: Double therapy (cyclosporine and azathioprine)
Number of subjects: 0
Study 2204696 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (cyclosporine, azathioprine, and corticosteroids)
Number of subjects: 0
Study 642793 — intervention group
Group type: EXPERIMENTAL
Intervention: Protected Environment (PE)
Number of subjects: 145
Study 642793 — intervention group
Group type: COMPARATOR
Intervention: Systemic Antibiotics (SA)
Number of subjects: 145
Study 642793 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic Antibiotics (PA)
Number of subjects: 145
Study 642793 — intervention group
Group type: COMPARATOR
Intervention: Outside Protected Environment (PE)
Number of subjects: 145
Study 642793 — intervention group
Group type: COMPARATOR
Intervention: OAP Chemotherapy
Number of subjects: 145
Study 642793 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin-OAP + BCG
Number of subjects: 145
Study 31760958 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon (750 g/week)
Number of subjects: 63
Study 31760958 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod (750 g/week)
Number of subjects: 63
Study 31760958 — intervention group
Group type: COMPARATOR
Intervention: Control (normal eating habits, avoiding fish)
Number of subjects: 63
Study 31158607 — intervention group
Group type: EXPERIMENTAL
Intervention: E0703 (30 mg oral administration)
Number of subjects: 0
Study 28290765 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Interval Exercise (MIIE)
Number of subjects: 11
Study 28290765 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Exercise (HIIE)
Number of subjects: 11
Study 28290765 — intervention group
Group type: COMPARATOR
Intervention: All exercise protocols
Number of subjects: 11
Study 25857320 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen (PSA) screening
Number of subjects: 0
Study 25857320 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatectomy
Number of subjects: 0
Study 25857320 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 23248223 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental screening using Ages and Stages Questionnaire‐II (ASQ‐II) and Modified Checklist for Autism in Toddlers (M‐CHAT) with office staff assistance
Number of subjects: 2103
Study 23248223 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental screening using ASQ‐II and M‐CHAT without office staff assistance
Number of subjects: 2103
Study 23248223 — intervention group
Group type: COMPARATOR
Intervention: Developmental surveillance using age‐appropriate milestones at well visits
Number of subjects: 2103
Study 21664658 — intervention group
Group type: EXPERIMENTAL
Intervention: trabectedin+PLD
Number of subjects: 216
Study 19201404 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D power Doppler imaging
Number of subjects: 25
Study 19201404 — intervention group
Group type: COMPARATOR
Intervention: 2D Doppler imaging
Number of subjects: 25
Study 16721226 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasojejunal (NJ) feeding
Number of subjects: 31
Study 16721226 — intervention group
Group type: COMPARATOR
Intervention: Nasogastric (NG) feeding
Number of subjects: 31
Study 15278043 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoendoscopic elastic band ligation
Number of subjects: 100
Study 15278043 — intervention group
Group type: COMPARATOR
Intervention: Conventional elastic band ligation
Number of subjects: 100
Study 11408849 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 40
Study 11408849 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone
Number of subjects: 40
Study 9222732 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg twice daily
Number of subjects: 54
Study 9222732 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg three times daily
Number of subjects: 54
Study 9222732 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (compliant patients)
Number of subjects: 54
Study 9222732 — intervention group
Group type: COMPARATOR
Intervention: Smokers vs Non-smokers
Number of subjects: 54
Study 9222732 — intervention group
Group type: COMPARATOR
Intervention: Age comparison
Number of subjects: 54
Study 8500696 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic atrophic gastritis (CAG)
Number of subjects: 742
Study 8500696 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial gastritis
Number of subjects: 742
Study 8500696 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundic chronic atrophic gastritis
Number of subjects: 742
Study 8500696 — intervention group
Group type: COMPARATOR
Intervention: Endoscopy
Number of subjects: 742
Study 8500696 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoimmune gastritis
Number of subjects: 742